
A federal jury on Thursday ruled in favor of American Airlines Group Inc. in its long-running lawsuit where the iconic airline accused flight booking service Sabre Corp of charging excessive fees and suppressing competition. The ruling, however, awarded the carrier only $1 in damages.
Jurors reached a verdict on their fifth day of deliberations, following a three-week trial in federal court in Manhattan.The antitrust case had originally been brought by US Airways in 2011, two years before it merged with Fort Worth, Texas-based American.
Sabre, based in Southlake, Texas, operates an electronic network used by travel agents to search for and book flights listed by airlines. The company’s stock value rose more than 3% in after-hours trading following the outcome, in what may be seen as a victory for the booking agent.
US Airways, which was acquired by AA, had alleged that Sabre impeded travel agents and others from using less expense alternatives for booking seats, and imposed an unduly restrictive distribution agreement. Jurors found that Sabre had indeed harmed the carrier by willfully maintaining monopoly power, but found a lack of proof that Sabre unreasonably restrained trade through the challenged contract.
“We are pleased and gratified with this landmark verdict,” American said in a statement. “We expect this decision to discourage further misconduct by Sabre and bring needed competition to airline distribution.”
Sabre said it was disappointed with the verdict on the monopolization claim, but that the $1 award was “commensurate with the evidence presented.” Sabre said it was pleased with the verdict on the distribution agreement.
American had won about $15.3 million from Sabre in a 2016 trial, but an appeals court overturned the award in 2019.
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Meta Begins Defense After FTC Concludes Case in Landmark Antitrust Trial
May 15, 2025 by
CPI
UK Data Bill Still No Closer to Passage As Parliamentary ‘Ping-Pong’ Drags On
May 15, 2025 by
CPI
Regeneron Pharmaceuticals Awarded $271.2M in Damages Against Amgen
May 15, 2025 by
CPI
FTC Chair Proposes 15% Staff Reduction Amid Budget Constraints
May 15, 2025 by
CPI
UK Urges Antitrust Watchdog to Prioritize Growth and Clarity in Business Regulation
May 15, 2025 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Healthcare Antitrust
May 14, 2025 by
CPI
Healthcare & Antitrust: What to Expect in the New Trump Administration
May 14, 2025 by
Nana Wilberforce, John W O'Toole & Sarah Pugh
Patent Gaming and Disparagement: Commission Fines Teva For Improperly Protecting Its Blockbuster Medicine
May 14, 2025 by
Blaž Višnar, Boris Andrejaš, Apostolos Baltzopoulos, Rieke Kaup, Laura Nistor & Gianluca Vassallo
Strategic Alliances in the Pharma Sector: An EU Competition Law Perspective
May 14, 2025 by
Christian Ritz & Benedikt Weiss
Monopsony Power in the Hospital Labor Market
May 14, 2025 by
Kevin E. Pflum & Christian Salas